Allergy Immunotherapy: All Modalities Compared by Evidence

Allergy shots (SCIT) deliver allergen extracts via subcutaneous injection into the upper arm, requiring clinic visits with a mandatory 30-minute observation period after each dose. Sublingual immunotherapy (SLIT) delivers allergen under the tongue — as FDA-approved tablets for grass, ragweed, and dust mite, or as compounded drops. Both approaches drive the same core immune changes (Treg induction, IgG4 rise, mast cell desensitization), but SLIT uses 50-100 times higher doses to achieve comparable results through the oral mucosal route. SLIT has zero confirmed worldwide fatalities versus roughly 1 per 2.5 million injections for SCIT historically. SCIT retains an advantage for polysensitized patients needing custom multi-allergen formulations, as no FDA-approved tablet covers multiple unrelated allergens simultaneously.

Most patients notice symptom improvement within 3 to 6 months of starting immunotherapy, often coinciding with reaching the maintenance dose for SCIT or completing the first treatment season for SLIT. The AAAAI/ACAAI Practice Parameter states that clinical improvement is usually observed within 1 year of reaching maintenance dose. However, the disease-modifying benefit — relief that persists after stopping treatment — requires at least 3 years of therapy. Studies confirm that 2-year courses are insufficient for durable post-treatment benefit (Scadding GRASS trial, JAMA 2017). If no improvement occurs after 1 year at the maintenance dose with allergens correctly identified, discontinuation should be considered with your allergist.

Allergy immunotherapy is disease-modifying but not a permanent cure for all patients. Durham et al. (NEJM 1999) demonstrated that 3-4 years of grass pollen SCIT produced symptom relief lasting at least 3 years after stopping treatment — with no relapse detectable versus continued maintenance patients. Eng et al. (Allergy 2006) documented benefit persisting 12 years after a childhood SCIT course. However, skin-test reactivity gradually returns over years, and some patients relapse, particularly those who were polysensitized. The evidence strongly suggests that treatment duration of 3-5 years optimizes durability, and that a second course — if needed — tends to work faster than the first. Using the word 'cure' overstates the evidence; 'sustained remission' is more accurate.

Strong candidates for allergy immunotherapy have confirmed IgE-mediated sensitization (positive skin prick test or serum-specific IgE) to clinically relevant allergens, experience moderate-to-severe symptoms despite antihistamines or nasal corticosteroids, prefer disease modification over long-term symptom medications, and are committed to a 3-5 year treatment course. Per AAAAI/ACAAI guidelines, failure of pharmacotherapy is NOT required before offering AIT — its disease-modifying potential makes it appropriate as an earlier option for motivated patients. Children benefit particularly from asthma-prevention effects (PAT study: 50% reduction in new asthma cases, Jacobsen Allergy 2007). Contraindications include severe uncontrolled asthma (FEV1 below 70% predicted) and pregnancy (for initiation only — maintenance can continue).

Four sublingual immunotherapy tablets are currently FDA-approved in the United States. Grastek (ALK) treats timothy grass pollen and is approved for adults and children 5 and older. Ragwitek (ALK) treats short ragweed pollen and is approved for adults 18 and older. Oralair (Stallergenes) treats a five-grass mix (timothy, orchard, perennial ryegrass, Kentucky bluegrass, sweet vernal) and is approved for adults and children 10-65. Odactra (ALK/Merck) treats house dust mites and was recently expanded to include children 5-11 (February 2025). Each product treats only one allergen category — a significant limitation for the majority of allergy patients who are sensitized to multiple unrelated allergens.

Evidence suggests allergy immunotherapy can reduce the risk of asthma developing in children with allergic rhinitis, though a definitive randomized prevention trial has not been published. The PAT study (Jacobsen, Allergy 2007, 10-year follow-up) found that children who received 3 years of SCIT for grass or birch pollen rhinoconjunctivitis had significantly lower asthma rates 7 years after stopping treatment — 25% versus 45% in controls, corresponding to an odds ratio of 2.5. This NNT is approximately 5-6 children treated to prevent one asthma case. A separate grass SLIT-tablet trial (GAP study, Valovirta JACI 2018) showed reduced asthma symptoms and medication use but did not meet its primary endpoint of preventing formal asthma diagnosis. Honest clinical framing: AIT reduces asthma risk and medication burden in children with rhinitis; it does not guarantee asthma prevention.

Despite sharing the word 'immunotherapy,' allergy treatment and cancer treatment work through entirely different immune mechanisms. Allergy immunotherapy induces allergen-specific peripheral tolerance — training regulatory T cells to suppress IgE-driven mast cell reactions. Cancer immunotherapy (checkpoint inhibitors, CAR-T) enhances immune surveillance against tumor cells by blocking inhibitory signals like PD-1/PD-L1 or CTLA-4. The two approaches are essentially opposite in direction: allergy AIT quiets an overactive immune response, while cancer immunotherapy activates a suppressed one. Importantly, allergy immunotherapy predates cancer immunotherapy by roughly 100 years — Noon and Freeman published the first SCIT protocol in 1911, while checkpoint inhibitors earned a Nobel Prize in 2011. Both fall under the 'immunotherapy' umbrella only in the broad sense of treatments that work through immune modulation.

Over a 5-year horizon, allergy immunotherapy typically costs $3,000-$20,000 total for SCIT (depending on insurance and number of allergens) or $1,200-$15,000 for SLIT options. Lifelong antihistamines plus nasal corticosteroids cost $600-$2,400 annually in OTC and prescription costs — meaning a 5-year medication course runs $3,000-$12,000 without disease modification. Hankin et al. (Ann Allergy Asthma Immunol 2010) found that AIT-treated patients had 33% lower total healthcare costs than matched controls, with savings emerging within 3 months of starting treatment. The economic case for AIT strengthens when indirect costs are included — lost workdays (14 annually per allergy patient, Pokladnikova 2008) and productivity losses that disappear once symptom control improves.